接受免疫检查点抑制剂治疗的晚期黑色素瘤患者的基线中性粒细胞与淋巴细胞比值 - Suppr | 超能文献

Baseline neutrophil-to-lymphocyte ratio in patients with advanced melanoma treated with immune checkpoint inhibitors.

作者信息

Machet L, Zaragoza J, Finon A, Garnier M, Maillard H, Caille A

机构信息

Inserm U1253, University of Tours, Tours, France.

Department of Dermatology, Tours, France.

出版信息

Br J Dermatol. 2018 Jul;179(1):224. doi: 10.1111/bjd.16675. Epub 2018 May 8.

DOI:10.1111/bjd.16675

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Baseline neutrophil-to-lymphocyte ratio in patients with advanced melanoma treated with immune checkpoint inhibitors.接受免疫检查点抑制剂治疗的晚期黑色素瘤患者的基线中性粒细胞与淋巴细胞比值

Br J Dermatol. 2018 Jul;179(1):224. doi: 10.1111/bjd.16675. Epub 2018 May 8.

2

Baseline neutrophil-to-lymphocyte ratio in patients with advanced melanoma treated with immune checkpoint inhibitors: reply from the authors.接受免疫检查点抑制剂治疗的晚期黑色素瘤患者的基线中性粒细胞与淋巴细胞比值：作者回复

Br J Dermatol. 2018 Jul;179(1):224-225. doi: 10.1111/bjd.16689. Epub 2018 May 7.

3

Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population.基线中性粒细胞与淋巴细胞比值联合血清乳酸脱氢酶水平与日本晚期黑色素瘤人群中纳武单抗免疫治疗的结局相关。

Br J Dermatol. 2018 Jul;179(1):213-215. doi: 10.1111/bjd.16427. Epub 2018 Apr 24.

4

Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.接受免疫检查点抑制剂治疗的转移性黑色素瘤患者炎症标志物与疾病进展的关联

Perm J. 2018;22:17-149. doi: 10.7812/TPP/17-149.

5

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.治疗前中性粒细胞与淋巴细胞比值作为纳武单抗治疗晚期非小细胞肺癌患者预后的标志物。

Lung Cancer. 2017 Apr;106:1-7. doi: 10.1016/j.lungcan.2017.01.013. Epub 2017 Jan 25.

6

Prognostic factors of daily blood examination for advanced melanoma patients treated with nivolumab.纳武利尤单抗治疗晚期黑色素瘤患者每日血液检查的预后因素。

Biosci Trends. 2018 Sep 19;12(4):412-418. doi: 10.5582/bst.2018.01158. Epub 2018 Aug 29.

7

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.

8

Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma.纳武单抗进行的检查点免疫疗法用于治疗转移性黑色素瘤。

J Cancer Res Ther. 2018 Oct-Dec;14(6):1167-1175. doi: 10.4103/jcrt.JCRT_1290_16.

9

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.程序性细胞死亡蛋白1或联合程序性死亡蛋白1/细胞毒性T淋巴细胞相关抗原4抑制治疗转移性葡萄膜黑色素瘤的预后因素及结局

Eur J Cancer. 2017 Sep;82:56-65. doi: 10.1016/j.ejca.2017.05.038. Epub 2017 Jun 22.

10

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR）作为接受纳武单抗治疗的非小细胞肺癌（NSCLC）患者的预后标志物。

Lung Cancer. 2017 Sep;111:176-181. doi: 10.1016/j.lungcan.2017.07.024. Epub 2017 Jul 24.

引用本文的文献

1

Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study.低剂量干扰素-α预处理联合过继细胞治疗对标准（免疫）治疗耐药的转移性黑色素瘤患者：一项 I/II 期研究。

J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000166.